ANTISTENOCARDIN
-
| StockNo |
Product description |
| EB0280-424-02 |
ANTISTENOCARDIN
(DPYRIDAMOL) DRAGEE 25 MG X 30 |
| EB0280-424-26 |
ANTISTENOCARDIN
(DIPYRIDAMOL) DRAGEE 25 MG X 30 |
| EB0280-424-27 |
ANTISTENOCARDIN
(DIPYRIDAMOL) FILMTABL 75 MG X 30 |
| EB0280-424-28 |
ANTISTENOCARDIN
(DIPYRIDAMOL) AMPOULE 10MG/1 ML (0.5%) |
-
- COMPOSITION:
Dipyridamol 10mg/2ml in one ampoule;
25 mg in one dragee and
75 mg in one filmtablet
ACTION:
Antistenocardin is a coronary-dilator. It induces accumulation of
adenosine in the myocardium by blocking adenosine deaminase and
inhibition of the adenosine influx which is an endogenous coronary
dilator. The enhanced concentration of adenosine in the myocardium
leads to intensified ATP biosynthesis. Dipyridamol blolcks
phosphodiesterase and elevates AMP level which explains both its
coronary dilatory effect and its antiaggregation activity on
platelets. It also activates prostacyclin synthesis, which is a
potent endogenous vasodilator and platelet antiaggregation agent.
Cardiac output is not essentially changed. Blood pressure and the
rate of cardiac activity are insignificantly influenced by
therapeutic doses. It has a spasmolytic effect on the smooth muscles
of bronchi and intestines. It binds with the so-called protein of
acute phase (alphal acid glucoprotein) in the blood, increased
during physiological stress and a series of pathological states
(myocardial infarction, rheumatoid arthritis, etc.).
Antistenocardin is one of the drugs that are eliminated via the
so-called enterohepatic turnover, resulting in a considerable
prolongation of its action.
INDICATIONS:
Stable angina pectoris. Acute and chronic coronary insufficiency;
prophylaxis of myocardial infraction; additive to the treatment with
digitalis glycosides.
CONTRAINDICATIONS:
Generalized coronary sclerosis with stenosis of coronariess. Acute
myocardial infraction with collapse. |
SIDE EFFECTS:
"Steal syndrome" can be observed after the discontinuation
of the drug. Blood pressure reduction can be observed after the
administration of the usual doses in patients with hypotension.
Light gastrointestinal disturbances, headache, dizziness, blushing,
weakness, nausea after low doses, and peripheral vasodilation with
syncope - after high doses.
PRECAUTIONS:
It must not be administered as a mixture with other pharmaceuticals
in one syringe. It must not be administered intravenously in
precollapse and collapse.
DOSAGE AND ADMINISTRATION:
Perorally - with the usual dosage of 0.025-0.05 (1-2 dragees), 2-3
times daily. For coping with severe anginal paroxysms after
injection pretreatment, a maintenance dose of 1 dragee, 3-4 times
daily is prescribed; the dragees are taken one hour before meals.
The treatment course lasts for 25-30 days, with repetitions.
Parenterally - 1 ampoule up to three times daily, deeply,
intramuscularly in severe cases; intravenously - it is injected very
slowly, but not to subjects with hypotension.
MEDICINAL FORM AND PACKAGE:
Packages with 10, 50 and 100 ampoules of 10 mg/2 ml (0.5 %).
Packages with 30 and 1000 dragees.
Packages with 30 filmtablets of 25 and 75 mg.
STORAGE:
At moderate temperature (15-30° C).
EXPIRY:
2 (two) years.
|
